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REVIEW
Abstract: Angiogenesis plays an important role in the growth and progression of cancer.
The regulation of tumor angiogenesis depends on a net balance of angiogenic factors and
antiangiogenic factors, which are secreted by both tumor cells and host-infiltrating cells.
Numerous studies have indicated that assessment of angiogenic activity by either microvessel
density or expression of angiogenic factors in cancer can provide prognostic information
independent of conventional clinicopathological factors such as tumor staging. Some studies
also suggested that assessment of tumor angiogenesis may predict cancer response to
chemotherapy or radiotherapy. However, the most important clinical implication of tumor
angiogenesis is the development of a novel strategy of anticancer therapy targeting tumor
vessels instead of cancer cells. Antiangiogenic therapy aims to inhibit the growth of tumor,
and current evidence suggests that it works best in combination with conventional cytotoxic
chemotherapy. Recently, a monoclonal antibody against vascular endothelial growth factor,
which is one of the most potent angiogenic factors, has been approved for clinical use in
colorectal cancer patients after a clinical trial confirmed that combining the antibody with
standard chemotherapy regimen could prolong patient survival. The clinical implications of
angiogenesis in cancer are reviewed in this article.
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Angiogenesis
Angiogenesis refers to the sprouting of new blood vessels from pre-existing capillaries.
It is a multi-step process involving proliferation of activated endothelial cells,
migration of the endothelial cells to reach remote targets, assembly of the endothelial
cells into new capillary tubes, followed by the synthesis of a new basement membrane
and maturation of vessels with formation of a vascular lumen. Angiogenesis is different
from vasculogenesis, which involves de novo differentiation of endothelial cells from
in situ mesoderm-derived precursor cells. Although sprouting from pre-existing blood
vessels is the principal process in angiogenesis, recent evidence has suggested that
recruitment and in situ differentiation of bone marrow-derived endothelial progenitor
cells are involved in angiogenesis in physiological and pathological conditions
(Asahara et al 1999). Angiogenesis is a critical process in embryogenesis. In the
adult, new blood vessel formation is required in some physiological conditions such
as the female reproductive cycle, tissue repair, and wound healing. More importantly,
angiogenesis is now known to play an essential role in pathological conditions such
as cardiac and limb ischemia, diabetic retinopathy, rheumatoid arthritis, and neoplasms
(Carmeliet and Jain 2000).
The concept that tumor growth and metastasis are dependent on the development
of new blood vessels was first formulated by Folkman (1971), who suggested that a
solid tumor starts as a dormant avascular nodule which could only grow and develop
if it becomes vascularized. Neovascularization must occur to provide oxygen and
nutrients to the tumor cells. Furthermore, the immature neovessels enhance tumor
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cell entry into the circulation and hence distant metastasis
(Liotta and Stracke 1988). It is now also recognized that
neovascularization dependence goes beyond solid tumors;
it also plays an important role in the development of
hematological malignancies (Perez-Atayde et al 1997). The
understanding of the fundamental role of angiogenesis in
cancer growth and metastasis has led to tremendous interest
in research in its regulatory mechanisms and clinical
implications in the management of cancer patients in the
past three decades.
Regulatory mechanisms of cancer
angiogenesis
The control of tumor angiogenesis depends on a net balance
of several activators (angiogenic factors) and inhibitors
(antiangiogenic factors), which are secreted by both tumor
cells and host infiltrating cells such as macrophages and
fibroblasts. During tumor progression, environmental and
genetic changes induce an “angiogenic switch”, with either
upregulation of angiogenic factors or downregulation of
angiogenesis inhibitors (Hanahan and Folkman 1996).
Environmental signals that can trigger angiogenesis include
hypoxia, change in pH, metabolic stress, and cytokines from
inflammatory response (Shweiki et al 1992, 1995; Akagi et
al 1999). Angiogenesis is also potentiated by certain
oncogenes such as Src and Ras (Kerbel et al 1998; Rak et al
2000), and downregulated by certain tumor suppressor genes
such as p53 and von Hippel-Lindau genes (Pal et al 1997;
Bouvet et al 1998). There is also evidence that angiogenesis
may be stimulated by hormones such as androgen (Jain et
al 1998), progesterone (Wu et al 2004), and estrogen
(Dabrosin et al 2003), which may contribute to carcino-
genesis and tumor progression in hormone-dependent
cancers such as prostate and breast cancer.
The development of new blood vessels in a tumor starts
with the release of angiogenic factors, which bind to specific
receptors of endothelial cells of pre-existing blood vessels
to trigger the process of angiogenesis. In addition to
angiogenic factors, proteinases such as matrix metallo-
proteinases (MMPs) and plasminogen activators are required
to dissolve the extracellular matrix in front of the sprouting
vessels (Bergers et al 2000). During the process of
angiogenesis, endothelial cell adhesion molecules such as
integrin αvβ3 and vascular adhesion molecule-1 help to
connect new vessels with the pre-existing ones to produce
the intratumoral vascular network (Koch et al 1995; Eliceri
and Cherish 1999).
In the initial hypothesis of Folkman (1971), the
development of new blood vessels during angiogenesis was
presumed to originate from endothelial cells in pre-existing
vessels. However, there is now strong evidence from studies
in animal tumor models that tumor endothelial cells may
also be derived from circulating endothelial precursor cells
originating from the bone marrow (Asahara et al 1999;
Ruzinova et al 2003). Furthermore, it has been proposed
that other types of bone marrow progenitor cells from
different lineages, such as hematopoietic progenitor cells,
can be co-recruited to tumor angiogenesis foci (Lyden et al
2001). A recent study has demonstrated the presence of bone
marrow-derived circulating endothelial precursor cells in
human cancers (Peters et al 2005). However, the exact
contribution of bone marrow-derived circulating endothelial
precursor cells to the formation of neovessels in tumors
remains uncertain, and its regulatory mechanisms are also
far from clear. Besides sprouting from pre-existing host
vessels and development of new vessels from bone marrow-
derived endothelial progenitor cells, it has also been
proposed that by co-option, cancer cells can grow around
an existing host vessel and form vessel-like networks, a
process termed vascular mimicry, although the significance
of this tumor vascularization model is controversial (Holash
et al 1999).
There are more than 40 known endogenous inducers and
inhibitors of angiogenesis to date. Table 1 shows the
relatively well-characterized endogenous angiogenic and
antiangiogenic factors. The best characterized angiogenic
factor is vascular endothelial growth factor (VEGF), which
is secreted by almost all solid cancers (Leung et al 1989).
VEGF is a heparin-binding peptide with a specific mitogenic
effect on endothelial cells, and it also increases vascular
permeability. VEGF is the central mediator of tumor
angiogenesis stimulated by hypoxia and certain oncogenes.
The effects of VEGF on endothelial cells are mediated via
its receptors, Flt-1 and KDR (Veikkola et al 2000). Basic
fibroblast growth factor (bFGF) is another potent angiogenic
factor secreted by most solid tumors. It acts synergistically
with VEGF in inducing angiogenesis (Asahara et al 1995).
Platelet-derived endothelial cell growth factor (PD-ECGF),
also known as thymidine phosphorylase, stimulates
endothelial cell migration rather than proliferation, and its
angiogenic effect is mediated by the release of 2-deoxy-D-
ribose as a result of breakdown of thymidine by PD-ECGF
(Griffiths and Stratford 1997). Angiogenin, a peptide that
belongs to the family of pancreatic ribonucleases, is a potent
inducer of angiogenesis in vivo (Badet 1999). AngiopoietinsVascular Health and Risk Management 2006:2(2) 99
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are more recently identified mediators of angiogenesis.
Angiopoietin-1 binds to Tie-2, an endothelial cell specific
tyrosine kinase receptor, leading to endothelial cell
stabilization (Papapetropoulos et al 1999). In contrast,
angiopoietin-2 binds to Tie-2 and leads to endothelial cell
destabilization and vascular regression (Maisonpierre et al
1997). Cyclooxygenase-2 (Cox-2), an enzyme known to
regulate cellular processes such as apoptosis, also has an
angiogenic effect via thromboxane-A2 (Daniel et al 1999).
Tissue factor is a primary physiological initiator of blood
coagulation that has been shown to enhance tumor
angiogenesis (Daniel et al 1999). Among the antiangiogenic
factors, thrombospondin-1 is considered an important
inhibitor of tumor angiogenesis (Gupta et al 1999). Two
other potent antiangiogenic factors are angiostatin and
endostatin, which are produced by tumor cells themselves
and are generated by proteolysis of inactive circulating
precursors plasminogen and collagen XVIII, respectively
(O’Reilly et al 1996, 1997). It has been postulated that
endogenous inhibitors of angiogenesis produced by a tumor,
such as angiostatin and endostatin, may play an important
role in tumor dormancy.
Angiogenic factors secreted by tumor cells act in a
paracrine fashion on tumor endothelium during the different
phases of the tumor angiogenic process. There is recent
evidence that some of the angiogenic factors may act in an
autocrine fashion on the cancer cells. VEGF was initially
thought to be a specific angiogenic factor, and VEGF
receptors were thought to be expressed on the cell surface
of endothelial cells only. However, recent studies have
demonstrated that VEGF receptors are expressed on cancer
cells of several types of human cancers and may mediate
proliferation and invasion of cancer cells (Herold-Mende
et al 1999; Dias et al 2000). Our group has demonstrated
that VEGF receptors are expressed on several hepatocellular
carcinoma cell lines, and VEGF stimulates proliferation of
hepatocellular carcinoma cells (Liu et al 2005). The
autocrine effect of VEGF may explain in part the antitumor
effect observed with anti-VEGF antibody in combination
with chemotherapy in addition to its antiangiogenic effect.
Tyrosine kinase receptors of other angiogenic factors such
as bFGF and PD-ECGF have also been identified in cancer
cells of some human cancers (Dickson et al 2000; George
2003). The functional role of these receptors in cancer cells
has not been fully clarified yet. These tyrosine kinase
receptors are expressed in endothelial cells and they
mediate the angiogenic effects of the angiogenic factors
by modulating the signaling of these factors, hence they
are important targets for antiangiogenic therapy. Small
molecule inhibitors of these tyrosine kinase receptors that
compete with the adenosine 5'-triphosphate (ATP)-
binding site of the catalytic domain of the tyrosine kinases
have been developed and are now under clinical trials in
cancer patients.
Prognostic implications of cancer
angiogenesis
Because cancer angiogenesis is related to tumor growth and
metastasis, assessment of tumor angiogenesis activity may
be useful in prognostic prediction. Weidner et al (1991) first
reported the prognostic significance of tumor angiogenesis
in breast cancer patients. Tumor neovascularization was
quantified by immunohistochemistry using endothelial
markers to stain microvessels, which are not seen in a
conventional histological examination. After
immunostaining, the entire tumor section was scanned at
low power (x 40) field to identify “hot spots”, which are the
areas of the highest neovascularization. Individual
microvessels were then counted under a high power (x 200)
field to obtain a vessel count in a defined area, and the
average vessel count in five hot spots was taken as the
microvessel density (MVD). Commonly used endothelial
markers for assessing MVD include CD31, CD34, and von
Willebrand factor (vWF). Subsequent to the study by
Weidner et al, numerous studies have shown the prognostic
Table 1 Endogenous angiogenic and antiangiogenic factors
Angiogenic factors Antiangiogenic factors
Vascular endothelial growth factor Thrombospondin-1, 2
Acidic and basic fibroblast growth
factors Endostatin
Transforming growth factor-α/β Angiostatin
Platelet-derived endothelial cell
growth factor Interferon-α/β
Hepatocyte growth factor Interleukin-12
Tumor necrosis factor-α Platelet factor 4 fragment
Epidermal growth factor Angiopoietin-2
Placental growth factor Human macrophage
metalloelastase
Tissue factor Tissue inhibitor of
metalloproteinase-1/2
Interleukin-6/8 Vascular endothelial growth
inhibitor
Angiogenin Vasostatin
Angiopoietin-1 Anti-thrombin III fragment
Cyclooxygenase-2 Osteopontin fragment
Nitric oxideVascular Health and Risk Management 2006:2(2) 100
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significance of tumor MVD on survival and/or disease
recurrence after surgical resection of different cancers, some
showing that tumor MVD was a prognostic factor
independent of conventional pathological prognostic factors
(Maeda et al 1995; Takebayashi, Akiyama, et al 1996; Ellis
et al 1998; Igarashi et al 1998). Assessment of tumor
angiogenesis may be particularly useful in prognostic
classification of patients with apparently early cancer by
conventional tumor staging, some of whom may still develop
early recurrence or metastasis despite being staged as having
early cancers by conventional parameters such as tumor size.
In a study conducted by our group, tumor MVD was found
to be an independent prognostic factor in patients with small
hepatocellular carcinomas <5 cm (Poon et al 2002). Tumor
angiogenesis is not only of prognostic value in solid cancers,
but it may also predict prognosis in patients with
hematological malignancies. Studies have demonstrated
adverse prognosis in leukemia patients with high bone
marrow angiogenesis (Molica et al 2002; Rabitsch et al
2004). Overall, most studies showed that the degree of
neovascularization in various human cancers is a prognostic
indicator. However, there remains some controversy
regarding the prognostic value of tumor MVD because
negative results have been demonstrated in a few studies
(Ellis et al 1998; Torres et al 1999; Pietra et al 2000). The
inconsistent results may be related to the lack of a
standardized and objective method of assessing tumor MVD.
The counting of microvessels in selected hot spots under
microscopy is likely to be associated with subjective bias
and inter-observer variation, which is further aggravated
by the lack of a standardized site of tumor sampling in
retrospective studies that employed archived tumor
specimens. The use of different endothelial markers in
different studies is also a potential source of variation.
Automated computerized image analysis for quantifying the
MVD may reduce subjective bias during the counting
process (Poon et al 2002). In a study of breast cancer, tumor
MVD obtained by automated computerized image analysis,
but not the MVD obtained by manual counting, was an
independent prognostic factor (Acenero et al 1998). The
use of more specific antibodies to stain activated endothelial
cells has also been proposed to improve tumor MVD
assessment. Immunostaining for integrin αvβ3, which is a
vascular endothelial adhesion molecule upregulated in
angiogenesis, may allow selective staining of activated
endothelial cells (Gasparini et al 1998).
The evaluation of expression of angiogenic factors in
tumor specimens provides an alternative to MVD in
assessing tumor angiogenic activity. This method may
potentially reduce the bias associated with the selection of
hot spots for MVD evaluation, and may provide more
functional information on the tumor angiogenic activity than
MVD. VEGF is the most widely studied angiogenic factor
for its clinical significance. Numerous studies have
demonstrated that tumor overexpression of VEGF correlates
with high tumor MVD and is associated with advanced
tumor stage or tumor invasiveness in various common
human cancers (Maeda et al 1996; Kitadai et al 1998; Seo
et al 2000; Verstovsek et al 2002). In some studies, VEGF
expression in the tumor has been shown to be a prognostic
factor independent of conventional prognostic factors
(Maeda et al 1996; Seo et al 2000). VEGF expression in
cancer cells has also been shown to be a prognostic factor
in hematological malignancies (Verstovsek et al 2002). The
effect of VEGF on angiogenesis depends on not only tumor
cell expression of VEGF, but also on the VEGF receptors
in the endothelial cells. A study from our group showed
that the VEGF receptor Flt-1 was upregulated in the
endothelial cells of hepatocellular carcinoma and correlated
significantly with the VEGF level in the tumor and
intrahepatic metastasis (Tokunaga et al 1998). The
overexpression of other angiogenic factors such as PD-
ECGF (Takebayashi, Aklyama, et al 1996; Matsumura et al
1998; Konno et al 2001), bFGF (Yamanaka et al 1993; El-
Assal et al 2001), transforming growth factor (TGF)-β
(Friess et al 1993; Maehara et al 1999; Saito et al 1999),
angiogenin (Shimoyama et al 1996; Etoh et al 2000), tissue
factor (Seto et al 2000; Poon, Lau, Ho, et al 2003), and
COX-2 (Cianchi et al 2001; Tang et al 2005) in various
cancers has been shown to correlate with advanced tumor
stage and decreased patient survival.
The majority of angiogenic factors are soluble and
diffusible peptides. Hence, the circulating level of
angiogenic factors has been investigated as a surrogate
marker of the angiogenic activity of the tumors. This may
have advantages in clinical application because the
measurement of circulating angiogenic factors is a
convenient and noninvasive approach that does not require
tumor specimens, and it can be repeated before and after
operation or other treatments. Dynamic contrast enhanced
magnetic resonance and computed tomography are widely
used in monitoring tumor angiogenesis before and after
antiangiogenic therapy. Compared with these complex
imaging assays of tumor vascularity, measurement of
circulating angiogenic factors as biomarkers is easier and
less expensive. The concentration of circulating angiogenicVascular Health and Risk Management 2006:2(2) 101
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factors can be measured easily by enzyme-linked
immunosorbent assay (ELISA). Folkman’s group first
reported a significant association between high serum or
urine levels of bFGF and progressive disease in patients
with different types of cancers (Nguyen et al 1994).
Subsequently, it was also shown that serum VEGF levels of
cancer patients were significantly higher than those of
healthy controls (Yamamoto et al 1996). The clinical
significance of circulating angiogenic factors in various
types of cancers has been studied extensively, and a detailed
review of the topic by our group has been previously
published (Poon, Fan, Wong, et al 2001). Most studies
evaluated the prognostic value of preoperative levels of
circulating angiogenic factors and suggested a prognostic
value of circulating level of angiogenic factors in cancer
patients. The prognostic significance of circulating VEGF
has been most widely studied (Jacobson et al 2000;
Yoshikawa et al 2000; Aguayo et al 2002; Werther et al
2002; Poon et al 2004). There are data that suggest the
prognostic significance of the circulating levels of other
angiogenic factors such as bFGF (Poon et al 2001a) and
PD-ECGF (Shimada et al 2002). Because of its pivotal role
in angiogenesis, VEGF appears to be the most promising
angiogenic biomarker. The prognostic value of serum VEGF
may have significant clinical implications because it can be
used before an operation to select patients with more
invasive tumors who may benefit from neoadjuvant therapy
or alternative treatments (Poon et al 2001b). However, there
is still some controversy regarding the clinical value of
measurement of serum VEGF level because the VEGF in
the circulation is found largely in the platelet, and there is a
debate whether the serum VEGF level truly reflects tumor
expression of VEGF or whether there are other possible
sources of circulating VEGF, such as the blood cells (Poon,
Fan, Wong, et al 2001). More recent studies since our last
review in 2001 have provided better insight into the
significance of circulating angiogenic factors. In a study by
our group, we demonstrated that the serum VEGF per
platelet, which reflects the platelet load of VEGF in the
circulation, correlated positively with tumor expression of
VEGF in patients with hepatocellular carcinoma (Poon, Lau,
Cheung, et al 2003). In recent years, there have been several
reports on the use of circulating VEGF in predicting or
monitoring response to antiangiogenic therapy in clinical
trials. There is some evidence that post-treatment decline in
circulating VEGF levels is associated with response or
stabilization of the disease (Drake et al 2003; Hernberg et
al 2003; Zangari et al 2004), but pre-treatment serum VEGF
level does not appear to predict treatment response (Stadler
et al 2004). Post-treatment change of circulating VEGF level
may be most valuable in monitoring response to
antiangiogenic therapy targeting VEGF (Drevs et al 2005).
Theoretically, measurement of circulating angiogenic factors
may also be of value in selecting the optimum antiangiogenic
therapy, but so far there have been little data on this aspect.
Recently, there is evidence that measurement of soluble
VEGF receptors, in addition to serum VEGF level, may also
provide prognostic information in cancer patients (Hu et al
2004). The ratio of VEGF and soluble VEGFR1 has been
shown to provide better prognostic value than serum VEGF,
VEGFR1 or VEGFR2 alone (Hoar et al 2004; Aref et al
2005).
A few studies have evaluated the relationship between
tumor angiogenesis and tumor response to chemotherapy
and/or radiotherapy in gastrointestinal cancers. As tumor
growth depends on angiogenesis, the rate of tumor cell
proliferation is related to angiogenic activity. The
microvascularization of the tumor may also affect tissue
distribution of anticancer drugs. Furthermore, the degree
of intratumoral hypoxia, which is an important determinant
of tumor response to radiotherapy, is also influenced by
angiogenesis.
 Hence, it is reasonable to speculate that there
may be a relationship between the angiogenic activity of a
tumor and its responsiveness to cytotoxic drugs or
radiotherapy. Dirix et al (1997) first showed that serum
VEGF and bFGF levels were higher in progressive disease
compared with responsive disease in patients treated with
chemotherapy for metastatic cancers from various origins.
Subsequently, Hyodo et al (1998) studied 34 patients with
metastatic gastric or colorectal cancers treated with systemic
chemotherapy and found that a low pre-treatment plasma
VEGF level was associated with a significantly higher
response rate and better prognosis; such a predictive power
was not observed with carcinoembryonic antigen (CA)-19.9
levels. Another study showed that high pre-treatment serum
VEGF levels were predictive of poor response and survival
in patients undergoing chemoirradiation for esophageal
squamous cell carcinoma (Shimada et al 2001).
While most studies have suggested an adverse prognostic
value of high serum VEGF level and possible value in
predicting or monitoring tumor response to antiangiogenic
or other anticancer therapies, thus far it has not been
successfully translated to clinical use in bedside. In addition
to the fact that results on its prognostic and predictive value
of various studies in the literature are not entirely consistent,
the range of serum VEGF level varies widely among studiesVascular Health and Risk Management 2006:2(2) 102
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of different cancers, and there is substantial overlap of the
serum levels of cancer patients and healthy subjects. This
makes it difficult to define a cutoff value for use in individual
cancer patients and hence limits its potential to become a
clinically useful biomarker.
Therapeutic implications of tumor
angiogenesis
The potential therapeutic implications of tumor angiogenesis
were envisaged by Folkman (1971) when he first introduced
the concept of tumor angiogenesis. Tumor cells were the
target of conventional cytotoxic chemotherapy. The
proliferating endothelial cells that are present in all cancers
provide a common target in the cancers for a novel
anticancer therapy, which may have the following theoretical
advantages over cytotoxic chemotherapy: (1) The
microvascular endothelial cells are genetically stable cells
with an extremely low mutation rate, and hence drugs
targeted at the endothelial cells are less likely than cytotoxic
drugs to induce drug resistance; (2) Since antiangiogenic
therapy targets the specific immature characteristics of tumor
vasculature, which differs from normal quiescent
vasculature, little or no toxicity has been demonstrated in
pre-clinical studies (Burke and DeNardo 2001); (3)
Endothelial cells are directly exposed to bloodborne agents,
circumventing the problem of drug delivery to tumor cells,
which is a major obstacle to conventional anticancer therapy;
(4) Tumor blood flow is measurable in the clinic, allowing
monitoring of the therapeutic efficacy of antiangiogenic
therapy.
Antiangiogenic therapy can be classified according to
their mechanisms of action (Table 2). The first approach is
to block the angiogenic factors or receptors, of which VEGF
and VEGF receptors have been the most commonly targeted
ones because of their central role in tumor angiogenesis. In
nude mice models, antibody against VEGF or blockage of
VEGF receptors could inhibit the growth of human
xenotransplants of different cancers such as gastric
carcinoma (Kamiya et al 1999), colonic carcinoma
(Shaheen, Ahmad, et al 2001), pancreatic carcinoma
(Solorzano et al 2001), and hepatocellular carcinoma (Liu
et al 2005). Inhibition of multiple angiogenic factors may
be more effective than inhibition of a single angiogenic
factor because a tumor may be able to overcome the effect
of inhibition of one angiogenic factor by upregulated
expression of other angiogenic factors. A recent study
showed that the use of a tyrosine kinase inhibitor for multiple
angiogenic factor receptors including VEGF, bFGF, and PD-
ECGF receptors was effective in improving survival in mice
bearing colon cancer liver metastasis (Shaheen, Tseng, et al
2001). Several drugs targeting multiple tyrosine kinase
receptors of angiogenic factors are being developed and
tested in pre-clinical studies or phase I/II clinical trials. A
second approach of antiangiogenic therapy is to use drugs
that directly inhibit the proliferation or survival of
endothelial cells. Some of the naturally occurring
antiangiogenic factors known to be expressed by tumors
Table 2 Classes of antiangiogenic agents
Antiangiogenic mechanisms Examples
Inhibitors of angiogenic factors or receptors
Monoclonal antibodies against angiogenic factors Bevacizumab (monoclonal anti-VEGF antibody)
Antibodies that act as soluble receptors of angiogenic factors  VEGF Trap (Inhibitor of VEGFR1 and VEGFR-2)
Inhibitors of tyrosine kinase receptors for angiogenic factors PTK787/ZK225 (blocks VEGF receptors)
SU11248 (blocks VEGFR-1 and -2,
FLT3, KIT, PDGFR-α and -β)
BAY43-9006 (blocks VEGFR-2 and 3,
PDGFR-β)




Inhibitors of extracellular matrix breakdown
Inhibitors of matrix metalloproteinases Marimastat
Neovastat
Inhibitors of vascular adhesion molecules
Inhibits integrin αvβ3 receptor Vitaxin
Abbreviations: PDGFR, platelet-derived growth factor receptor;  VEGF, vascular endothelial growth factor;  VEGFR, vascular endothelial growth factor receptor.Vascular Health and Risk Management 2006:2(2) 103
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have been shown to inhibit tumor growth in animal models
of cancers (Schmitz et al 2004; te Velde et al 2005).
Thalidomide is a drug that inhibits endothelial proliferation,
but the exact mechanism is unclear. It has been found to
inhibit the growth of human cancer implanted in nude mice
(Kotoh et al 1999). A third approach is to use drugs that
prevent the degradation of extracellular matrix and basal
membrane, a step essential for angiogenesis. For example,
an inhibitor of MMP-2 and MMP-9 has been shown to
reduce tumor vascularity and liver metastasis in human colon
cancer xenograft implanted in mice (Oba et al 2002).
 A fourth
approach is to inhibit vascular cellular adhesion molecules
such as integrin αvβ3 (Lode et al 1999). Based on currently
available evidence, blockage of angiogenic factors such as
VEGF offers the greatest promise, while drugs directly
inhibiting the proliferation of endothelial cells, such as
endostatin and thalidomide, have not been found to have
significant antitumor efficacy in clinical trials.
Some clinically available drugs previously known for
other effects are now recognized to have an antiangiogenic
effect as well. For example, interferon-alpha is an
immunomodulatory agent that has been used in the treatment
of unresectable hepatocellular carcinoma. It has been
recently reported that interferon-alpha inhibits the growth
of human hepatocellular carcinoma (HCC) implanted in
nude mice by an antiangiogenic effect probably mediated
by inhibition of bFGF and VEGF production (Wang et al
2000). However, interferon-alpha monotherapy has not been
found to be an effective therapy for advanced HCC and is
associated with significant side effects (Llovet et al 2000).
Celecoxib, a COX-2 inhibitor, is an antiinflammatory drug
that can induce apoptosis, and it is used to inhibit the growth
of adenomatous colorectal polyps in patients with familial
adenomatous polyposis. A recent study showed that
celecoxib can suppress tumor growth in nude mice by
antiangiogenic effect (Leahy et al 2002).
A combination of antiangiogenic agents may be more
effective than monotherapy. Although antiangiogenic
therapy is thought to have a low risk of drug resistance,
there is some preclinical and clinical evidence that suggests
the possibility of acquired drug resistance in antiangiogenic
therapy (Kerbel 2001). In particular, indirect antiangiogenic
therapy that depends on the blockade of tumor-derived
angiogenic factors has a high risk of drug resistance, because
tumor cells may eventually release a different angiogenic
factor. The expression of multiple angiogenic factors in a
cancer implies possible antiangiogenic drug evasion by
alternate pathways of angiogenesis in tumor cells, likely
induced by antiangiogenic drug-mediated increases in tumor
hypoxia. Definitive preclinical evidence of antiangiogenic
drug resistance has been recently reported in a study, which
showed that phenotypic resistance to VEGFR2 blockade
emerged as tumors regrew during treatment with function-
blocking antibody to VEGFR2 after an initial period of
growth suppression, and that this resistance to VEGF
blockade involved reactivation of tumor angiogenesis
independent of VEGF and associated with hypoxia-mediated
induction of other proangiogenic factors (Casanovas et al
2005). The combination of two antiangiogenic agents may
delay or avoid the problem of drug resistance. This may
involve combination of two drugs targeting different
angiogenic factors (Ciardiello et al 2000), or a combination
of antiangiogenic drugs that act through different
mechanisms to obtain a synergistic effect and to reduce the
chance development of drug resistance. For example, it has
been shown that combination of soluble vascular endothelial
growth factor [VEGF] receptor 1 as an indirect inhibitor of
angiogenesis and endostatin as a direct inhibitor of
endothelial proliferation synergistically enhanced their
inhibitory effect on the growth of hepatocellular carcinoma
in a rat model (Graepler et al 2005). Combination of an
antiangiogenic agent with a vascular disrupting agent is
another approach that has been shown to achieve significant
enhancement of antitumor efficacy in models of human
cancers, and such combination therapy may have significant
therapeutic benefit even in tumors insensitive to either
treatment alone (Shi and Siemann 2005).
Early clinical trials of antiangiogenic therapy in human
cancers involved the use of antiangiogenic drugs as
monotherapy for patients with advanced cancers refractory
to conventional chemotherapy. Thalidomide is one of the
earliest antiangiogenic drugs tested in clinical trials.
Although there is some evidence of significant efficacy of
thalidomide for multiple myeloma (Singhal et al 1999),
results of thalidomide monotherapy for advanced cancers
of other organs were generally unsatisfactory, with low
tumor response rates (Reiriz et al 2004; Lin et al 2005).
Trials of monotherapy using another antiangiogenic agent,
endostatin, for advanced solid cancers were also
disappointing (Thomas et al 2003). Antiangiogenesis is
mainly a cytostatic therapy that it is likely to have the greatest
effect when combined with cytotoxic chemotherapy or
radiotherapy. It has been shown in animal studies that a
combination of VEGF neutralizing antibody or VEGF
receptor antibody and cytotoxic chemotherapy drug was
more effective than either agent alone as anticancer therapyVascular Health and Risk Management 2006:2(2) 104
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(Klement et al 2000; Matsumoto et al 2000). Lee et al (2000)
showed that anti-VEGF monoclonal antibody could augment
the tumor response to radiation in human colon
adenocarcinoma xenograft in mice, possibly because the
anti-VEGF monoclonal antibody treatment can compensate
for the resistance to radiation induced by hypoxia. However,
the benefit of combination of antiangiogenic therapy with
radiation therapy remains uncertain. As demonstrated by a
recent study (Casanovas et al 2005), tumor response to
antiangiogenic therapy can lead to hypoxia and upregulation
of hypoxia-related growth factors, which might ultimately
make these cells more aggressive.
The combination of a recombinant humanized anti-
VEGF monoclonal antibody, bevacizumab (Avastin,
Genentech, South San Francisco, CA, USA), with a
chemotherapy regimen consisting of irinotecan, 5-
flourouracil, and leucovorin, has been recently demonstrated
to prolong survival of patients with metastatic colorectal
cancer compared with patients who received the
chemotherapy regimen alone in a large randomized trial
(Hurwitz et al 2004). This has led to the approval of
bevacizumab by the US Food and Drug Administration for
the treatment of patients with metastatic colorectal cancer.
Promising data are emerging showing that bevacizumab in
combination with chemotherapy improves tumor response
or survival of patients with other cancers such as lung cancer,
breast cancer, ovarian carcinoma, renal cell carcinoma,
pancreatic cancer, and other tumor types (Johnson et al 2004,
Miller, Chap, et al 2005, de Gramont and Van Cutsem 2005).
An alternative approach of targeting VEGF pathway is the
use of small molecule inhibitors that inhibit VEGF receptors.
Several of these tyrosine kinase inhibitors, including
PTK787/ZK 222584 (Vatalanib), SU5416, ZD6474, and
BAY 43-9006 (Sorafenib) are now in clinical trials in
patients with advanced cancers (Heymach et al 2004; Miller,
Trigo, et al 2005; Strumberg et al 2005; Thomas et al 2005).
Most of these tyrosine kinase receptor inhibitors have
inhibitory effect on other tyrosine kinase receptors, and this
may theoretically be an advantage over monoclonal antibody
against VEGF, which has a single action of inhibition of
VEGF. For example, PTK787/ZK 222584 inhibits PD-
ECGF and c-kit protein receptor kinases in addition to VEGF
receptors. These small molecule inhibitors are orally active,
have a favorable safety profile and can be easily combined
with other forms of chemotherapy. However, preliminary
data from some of the early trials did not reveal a dramatic
antitumor effect as demonstrated with anti-VEGF antibody
therapy. In a phase II trial testing SU5416 (an inhibitor of
VEGF and kit receptor tyrosine kinases) in patients with
advanced soft tissue sarcoma, it was observed that VEGF
receptor or kit inhibition was incomplete in at least some
cases, providing a possible explanation for the observed lack
of antitumor activity (Heymach et al 2004). The
development of resistance of cancer cells to tyrosine kinase
inhibitors is another problem that needs to be addressed to
enhance the clinical efficacy of tyrosine kinase inhibitors
(Ozvegy-Laczka et al 2005). Currently, more than 40
angiogenesis inhibitors are undergoing clinical trials in
patients with various cancers, and in addition to
bevacizumab, several other agents have reached phase III
trials. The role of antiangiogenic therapy in cancer treatment
is going to expand with the availability of more effective
agents in the future.
Currently most studies on measurement of angiogenic
factors focus its role in monitoring response and predicting
outcome of treatment. A clinical study that evaluates the
role of measurement of angiogenic factors in selecting
patients for specific therapies has not yet been published.
Clinical use of antiangiogenic therapy in cancer treatment
is still in its early phase of development. Measurement of
angiogenic factors may be useful in selecting patients for
specific therapies targeting at individual angiogenic factors.
This is worthy of evaluation in future clinical trials on
antiangiogenic therapy.
Conclusions
In recent years, tumor angiogenesis research has been
translated from the laboratory to the bedside at a rapid pace.
Hence, it is important for clinicians involved in care of
cancer patients to be aware of the potential clinical
implications of tumor angiogenesis. The vast number of
studies on the prognostic impact of tumor angiogenesis has
shown a direct correlation between tumor vascularity and
prognosis. However, routine clinical assessment of tumor
angiogenesis as a prognostic parameter cannot be justified
with the existing data. With few exceptions, available data
were derived from retrospective studies using archived
surgical specimens. Large prospective studies using a
standardized methodology and prospectively collected data
are mandatory to validate the prognostic significance of
tumor angiogenesis. Furthermore, the assessment of tumor
MVD or expression of angiogenic factors requires tumor
specimens, which may not be available in all cases of cancer
patients. The prognostic role of circulating angiogenic
factors remains controversial. Recent studies have suggested
that color Doppler ultrasonography may provide a reliableVascular Health and Risk Management 2006:2(2) 105
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preoperative quantitation of tumor angiogenesis and
prognostic information in cancer patients (Ogura et al 2001;
Chen et al 2002). Other methods of noninvasive assessment
of tumor angiogenesis, such as magnetic resonance imaging
conjugated with biotinylated antibodies to integrin αvβ3, and
positron emission tomography with specific radiolabelled
glycopeptide to determine integrin αvβ3 status in the tumors,
are under investigation (Sipkins et al 1998; Haubner et al
2001). Such noninvasive methods for assessing tumor
angiogenesis may not only provide prognostic information,
but may also represent a useful tool to monitor changes in
tumor microvasculature in response to antiangiogenic
therapy.
Antiangiogenic therapy is a novel strategy for treating
cancers that has been shown to increase patient survival in
combination with conventional chemotherapy. One major
problem confronting clinical trials of antiangiogenic therapy
is the lack of an established surrogate marker to measure
antiangiogenic activity in vivo in cancer patients. Tumor
response in terms of shrinkage alone may not be an
appropriate index of treatment efficacy because of the
cytostatic nature of the treatment. The ability of an
antiangiogenic drug to induce prolonged stabilization of the
disease and increase survival may be more meaningful end-
points for clinical trials on antiangiogenic therapy.
Noninvasive imaging of tumor vascularity may provide a
better index of the response of the tumor to antiangiogenic
therapy. Currently, antiangiogenic therapy is being tested
in combination with chemotherapy mainly in end-stage
inoperable disease. The role of antiangiogenic drugs in other
clinical settings such as neoadjuvant or adjuvant therapy in
combination with surgery remains to be studied. With the
approval of the anti-VEGF monoclonal antibody
bevacizumab for clinical use in cancer patients, it is
foreseeable that active research will be directed to the study
of the role of antiangiogenic therapy using various other
agents, leading to novel angiogenesis-based treatments in
the near future.
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